BioWorld

Jan. 17, 2002

View Archived Issues

Inspire Comes Up Short In Phase III Study; Stock Falls 73 Percent

Inspire Pharmaceuticals Inc. said it’s not likely that the first Phase III trial of its lead product for dry eye will reach its endpoints. The negative news sent Inspire’s stock tumbling 73 percent. Read More

Immunex’s Enbrel Continues Growth, Receives 4th Approval

Read More

Merck Conducting Human Safety Trials Of Anti-HIV T-Lymphocyte Killers; No Antibodies Need Apply

Read More

Zonagen Opts To Move Forward Rather Than Explore Alternatives

Read More

Other News To Note

Read More

Correction/Clarification

Read More

La Jolla Raises $51.6M Privately To Fund Late-Stage Clinical Trials

Read More